Antibody persistence to diphtheria toxoid, tetanus toxoid,
Humans
Antibodies, Bacterial
/ blood
Haemophilus Vaccines
/ immunology
Infant
Female
Immunization, Secondary
Male
Vaccines, Combined
/ immunology
Child, Preschool
Bordetella pertussis
/ immunology
Haemophilus influenzae type b
/ immunology
Diphtheria-Tetanus-Pertussis Vaccine
/ immunology
Whooping Cough
/ prevention & control
Poliovirus Vaccine, Inactivated
/ immunology
Thailand
Tetanus Toxoid
/ immunology
Diphtheria Toxoid
/ immunology
Diphtheria-Tetanus-acellular Pertussis Vaccines
/ immunology
Diphtheria
/ prevention & control
Haemophilus Infections
/ prevention & control
Diphtheria
Haemophilus influenzae type b
acellular
childhood
pertussis
tetanus
vaccine antibody
whole cell
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
31 Dec 2024
31 Dec 2024
Historique:
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
16
5
2024
Statut:
ppublish
Résumé
Thailand has incorporated the whole-cell (wP) pertussis vaccine into the expanded program on immunization since 1977 and has offered the acellular pertussis (aP) vaccine as an optional vaccine for infants since 2001. We followed healthy children from a clinical trial (ClinicalTrials.gov NCT02408926) in which children were randomly assigned to receive either pentavalent (DTwP-HB-Hib) or hexavalent (DTaP-IPV-HB-Hib) vaccines for their primary series (administered at 2, 4, and 6 months) and first booster vaccination (18 months). Both groups received Tdap-IPV as a second booster at the age of 4 y. Blood samples were collected for evaluation of antibody persistence to diphtheria toxoid (DT), tetanus toxoid (TT), and
Identifiants
pubmed: 38752802
doi: 10.1080/21645515.2024.2352909
doi:
Banques de données
ClinicalTrials.gov
['NCT02408926']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM